Dana-farber-cancer Institute Inc.

University of Arkansas

Mietamark Genetics, Inc.

Lynda Chin

Ronald A DePinho

Giovanni Tonon

Cameron W Brennan

Kenneth Carl Anderson

John D Shaughnessy

Ruben Carrasco

Ronald A Depinho

Kwok-kin Wong

Andrew J Aguirre

Zhihu Ding

Alex Stegh

Chang-Jiun Wu

Hyung Gee Kim

The present invention provides a set of DETERMINANTS (e.g., genes and gene products) that can accurately inform about the risk of cancer progression and recurrence, as well as methods of their use.

Signatures and determinants associated with prostate cancer progression and methods of use thereof

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the MCRs and/or alterations in the amount, structure, and/or activity of one or more of the markers is correlated with the presence of cancer.

Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human pancreatic adenocarcinoma. A variety of chromosomal regions (MCRs) and markers in the MCRs, are provided that are correlated with cancer. In particular, chromosomal regions and markers in the MCR 50.06-62.89 Mb of human chromosome 19, are provided, wherein alterations in the copy number of the MCR and/or alterations in the amount, structure, and/or activity of one or more of the markers in the MCR is correlated with the presence of pancreatic adenocarcinoma.

Compositions, kits, and methods for identification, assessment, prevention and treatment of pancreatic adenocarcinoma in humans

Compositions, kits and methods for identification, assessment, prevention and therapy of cancer

The invention provides methods and materials related to Bcl2L12 polypeptides and the biological activities of Bcl2L12 polypeptides. For example, the invention provides methods and materials related to identifying activators and inhibitors of Bcl2L12 polypeptide activities such as the ability to block apoptosis and promote cell growth and transformation. The invention also provides methods and materials for treating mammals having cancer.

Bcl2L12 polypeptide activators and inhibitors

The invention provides methods and materials for identifying and characterizing genes related to phenotypes such as cancer and cell survivability. Also provided in the invention are cells and transgenic, non-human mammals that can be used in these methods.

Identifying and characterizing genes

A non-human mammal having incorporated into its genome an expression construct in which nucleic acid encoding an oncogene is operably linked to an inducible promoter; the mammal further has a genetic mutation that causes it to have an increased susceptibility to cancer.

Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo

Growing community of inventors

Brookline, MA, United States of America

Lynda Chin